Ryvu Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Ryvu Therapeutics has a total shareholder equity of PLN195.3M and total debt of PLN88.5M, which brings its debt-to-equity ratio to 45.3%. Its total assets and total liabilities are PLN404.8M and PLN209.5M respectively.
Key information
45.3%
Debt to equity ratio
zł88.46m
Debt
| Interest coverage ratio | n/a |
| Cash | zł129.72m |
| Equity | zł195.31m |
| Total liabilities | zł209.52m |
| Total assets | zł404.84m |
Recent financial health updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Financial Position Analysis
Short Term Liabilities: RVU's short term assets (PLN293.9M) exceed its short term liabilities (PLN61.9M).
Long Term Liabilities: RVU's short term assets (PLN293.9M) exceed its long term liabilities (PLN147.6M).
Debt to Equity History and Analysis
Debt Level: RVU has more cash than its total debt.
Reducing Debt: RVU's debt to equity ratio has increased from 2.1% to 45.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RVU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RVU has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.7% each year